Unlike conventional ACT therapies, the TCR-based treatments rely on tumor antigen presentation by HLA complex; hence, mUM patients with HLA-A*02-positive tumors are eligible to receive genetically modified T cells therapies or non-cellular TCR-based therapy (Figure 2). The gene discussed is HLA-A; the disease is neoplasm.